Is Danger Lurking in Dendreon's Future?

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

No stock sums up biotech investing quite like Dendreon  (Nasdaq: DNDN  ) , the company behind a novel prostate cancer treatment called Provenge. In what amounts to a case study on unchecked optimism, Dendreon shares were still flying high just over a year ago on exuberant sales projections. Then things took a turn for the worse. Management pulled revenue guidance, and shares collapsed.

Before the collapse occured, management used a soaring outlook, and stock price, as an opportunity to raise cash. However, that money was raised in a way that might come back to haunt it in the not-too-distant future. Follow along in the following video as Brenton and David go into more detail on a future obligation that potential investors must be aware of.

If you want the full story behind the company, our own David Williamson just released his brand-new premium research report on Dendreon. Inside, he details every key issue facing the company and outlines just how Dendreon intends to regain its former glory. The report also comes with a full year of analyst updates, so claim your copy of this exclusive report today by clicking here now.


Read/Post Comments (1) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 06, 2012, at 6:18 PM, lebronz wrote:

    Wow, you're releasing multiple videos & articles on such a losing story of a biotech.

    This is only a GREAT TELL to poker player investors to BUY DNDN NOW!

    BTW, I like the background room partition.

    Very feng shui....

    No, the only danger lurking and what U2 Motley Fewlz should be focusing on is the trend of short interest numbers.

    Latest numbers will be released Friday at 4pm et.

    Expect to see another million+ shares shorted as certain hedgefunds/institutions continue to PURPOSELY DRIVE THE PRICE DOWNWARD (for period Oct 15-30) by flooding the they have been flooding almost 2 million shares per month since Feb when the new CEO who understands the importance of catering to his top 10-20 shareholders wishes.

    We'll be much higher than the current 47 million shares short! Bet on it!


    ps: Oops, you forgot to disclose that you're LONG DNDN DAVID (as you said in previous videos)! You're smart David to be long because CEO JJ will continue to underpromise the remainder of the year and over-deliver by next Summer (in < 9 months). Good luck and look forward to your next video on DNDN tomorrow.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2098908, ~/Articles/ArticleHandler.aspx, 10/23/2016 8:15:16 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
DNDNQ $0.00 Down +0.00 +0.00%
Dendreon Corp CAPS Rating: *
JNJ $113.44 Down -1.43 -1.24%
Johnson and Johnso… CAPS Rating: ****
MDVN $0.00 Down +0.00 +0.00%
Medivation CAPS Rating: ****